M. Morgan

Facility level variation in the utilization of neoadjuvant chemotherapy is associated with higher surgical morbidity for patients with advanced stage epithelial ovarian carcinoma.

E. Ko, R. Giuntoli, F. Simpkins, 2022, Gynecologic oncology.

527MO Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase 3 ATHENA–MONO study

F. Marmé, R. Kristeleit, A. Oaknin, 2022, Annals of Oncology.

Antiphospholipid Antibodies in Chronic Hypertension: The Value of Screening During Pregnancy

G. Macones, A. Marzullo, S. Parry, 1998, American journal of perinatology.

Detection of hypoxia in human squamous cell carcinoma by EF5 binding.

S M Evans, E M Lord, R. Weber, 2000, Cancer research.

Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer.

D. Torigian, I. Shih, R. Drapkin, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.